These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-β-lactamases. Feng K; Jia N; Zhu P; Sy S; Liu Y; Dong D; Zhu S; Zhang J; Liu Y; Martins FS; Gong H; Lv Z; Yu M; Sy SKB; Zhu Y J Antimicrob Chemother; 2021 Oct; 76(11):2875-2883. PubMed ID: 34383928 [TBL] [Abstract][Full Text] [Related]
23. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. Mikhail S; Singh NB; Kebriaei R; Rice SA; Stamper KC; Castanheira M; Rybak MJ Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182535 [TBL] [Abstract][Full Text] [Related]
25. Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia. Biagi M; Lamm D; Meyer K; Vialichka A; Jurkovic M; Patel S; Mendes RE; Bulman ZP; Wenzler E Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928733 [TBL] [Abstract][Full Text] [Related]
27. In vitro selection of aztreonam/avibactam resistance in dual-carbapenemase-producing Klebsiella pneumoniae. Niu S; Wei J; Zou C; Chavda KD; Lv J; Zhang H; Du H; Tang YW; Pitout JDD; Bonomo RA; Kreiswirth BN; Chen L J Antimicrob Chemother; 2020 Mar; 75(3):559-565. PubMed ID: 31722380 [TBL] [Abstract][Full Text] [Related]
28. In Vitro and In Vivo Evaluations of β-Lactam/β-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan. Yang TY; Hsieh YJ; Kao LT; Liu GH; Lian SH; Wang LC; Lin IL; Lin YT; Wang SF; Tseng SP; Lu PL Microorganisms; 2020 Dec; 8(12):. PubMed ID: 33322803 [TBL] [Abstract][Full Text] [Related]
29. Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from Pragasam AK; Veeraraghavan B; Shankar BA; Bakthavatchalam YD; Mathuram A; George B; Chacko B; Korula P; Anandan S Indian J Med Microbiol; 2019; 37(1):34-41. PubMed ID: 31424008 [TBL] [Abstract][Full Text] [Related]
30. Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope. Avery LM; Nicolau DP Int J Antimicrob Agents; 2018 Nov; 52(5):688-691. PubMed ID: 30044946 [TBL] [Abstract][Full Text] [Related]
32. Molecular β-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets. Mendes RE; Castanheira M; Woosley LN; Stone GG; Bradford PA; Flamm RK Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348155 [TBL] [Abstract][Full Text] [Related]
33. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria. Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329 [TBL] [Abstract][Full Text] [Related]
34. Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to Target Hayden DA; White BP; Bennett KK J Pharm Technol; 2020 Oct; 36(5):202-210. PubMed ID: 34752560 [No Abstract] [Full Text] [Related]
35. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens. Karaiskos I; Galani I; Souli M; Giamarellou H Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244 [TBL] [Abstract][Full Text] [Related]
36. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055 [TBL] [Abstract][Full Text] [Related]
37. In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013. Biedenbach DJ; Kazmierczak K; Bouchillon SK; Sahm DF; Bradford PA Antimicrob Agents Chemother; 2015 Jul; 59(7):4239-48. PubMed ID: 25963984 [TBL] [Abstract][Full Text] [Related]
38. Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. Sader HS; Carvalhaes CG; Arends SJR; Castanheira M; Mendes RE J Antimicrob Chemother; 2021 Feb; 76(3):659-666. PubMed ID: 33276387 [TBL] [Abstract][Full Text] [Related]